Persistent Fetal SVT in a COVID-19 Positive Pregnancy

BACKGROUND: Rapid introduction and spread of SARS-CoV-2 have posed unique challenges in understanding the disease, role in vertical transmission, and in developing management. We present a case of a patient with COVID-19 infection and fetus with new-onset fetal SVT. CASE: A 26-year-old gravida 4 par...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gloria, Stapley, Eric, Peterson, Sara, Parrott, Jessica, Clark-Ganheart, Cecily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742150/
https://www.ncbi.nlm.nih.gov/pubmed/35013695
http://dx.doi.org/10.1155/2022/9933520
Descripción
Sumario:BACKGROUND: Rapid introduction and spread of SARS-CoV-2 have posed unique challenges in understanding the disease, role in vertical transmission, and in developing management. We present a case of a patient with COVID-19 infection and fetus with new-onset fetal SVT. CASE: A 26-year-old gravida 4 para 2012 with third trimester COVID-19 infection was diagnosed with new onset fetal SVT. Successful cardioversion was achieved with flecainide. The patient was followed outpatient until induction of labor at 39 and 3/7 weeks of gestational age resulting in an uncomplicated vaginal delivery. Postpartum course was uncomplicated. CONCLUSION: Fetal SVT is a potential complication of maternal COVID-19 infection. The use of transplacental therapy with flecainide is an appropriate alternative to digoxin in these cases.

Ejemplares similares